Radiation-Induced Toxicity in the Era of Stereotactic Body Radiation Therapy—Lessons From NRG-BR001
Mené entre 2014 et 2018 sur 39 patients présentant plus d'1 métastase ayant pour origine un cancer du sein, du poumon non à petites cellules ou de la prostate (âge moyen : 63 ans ; 57 % d'hommes), cet essai de phase I évalue les toxicités limitant la dose d'un traitement par radiothérapie corporelle stéréotaxique
Successfully executing radiotherapy-based prospective clinical trials is challenging in a rapidly evolving clinical environment where commercially available technological advances may outpace high-level evidence of effectiveness. This is especially the case with the increasing use of stereotactic body radiation therapy (SBRT) in patients with metastatic solid tumors. Furthermore, the literature has a plethora of SBRT-based studies, often using different definitions of oligometastatic disease, diverse treatment planning systems, and variation in primary end points. This variety speaks to clinicians’ valuing well-designed, prospectively gathered evidence of efficacy to ultimately help define best practices. However, it is often not fully appreciated that there is no optimal design to assess technologies like SBRT. Nevertheless, the NRG Oncology consortium is to be congratulated on attempting to study the role of SBRT in a prospective fashion for patients with oligometastatic disease.
JAMA Oncology , éditorial en libre accès, 2020